


Celebrating 20 Years of Impact: C-Path Featured in Special BizTucson Anniversary Issue



This year, Critical Path Institute® (C-Path) proudly marks 20 years of advancing regulatory science and reshaping how new treatments are developed and delivered to individuals and families affected by Alzheimer's disease, Parkinson's, type 1 diabetes, rare and pediatric conditions, and more. To commemorate this milestone,?BizTucson?has published a special report titled?"Critical Path Institute: Moving Drugs to Market, Smarter, Faster for 20 Years, "?highlighting the organization's global impact since its founding in 2005.

The in-depth issue includes a milestone timeline of C-Path's achievements, powerful insights from founder Dr. Raymond Woosley, Board Chair Wainwright Fishburn, and Tammy McLeod of the Flinn Foundation, and highlights the organization's progress in key areas such as neurology and rare disease.

A feature on CEO Klaus Romero and President & COO Kristen Swingle offers a behind-the-scenes look at the leadership duo

steering C-Path into its next decade of innovation and growth. Additionally, the issue celebrates Swingle's recent recognition as one of? *BizTucson*'s 2025? *Women Leading the Region*—a well-deserved honor for her leadership and commitment to C-Path's mission.

Read the full special issue here.

Read Kristen Swingle's "Women Leading the Region" feature here.

We are proud to celebrate this 20-year milestone with our partners, collaborators, and community—and look forward to continuing our mission to improve global health for decades to come.



Desert Duo

Critical Path Institute's Dynamic Leadership Team

By Tara Kirkpatrick

Gritical Path Institute, a ground-breaking nonprofit driving better and taster drug development across the world, is led by a respected pair who are the ultimate tag team for science and structure.

De Klaus Romero, CEO, and Kristern Swingle, president and COO, are truly the glue behind a global public-president and COO, are truly the glue behind a global public-president and coop, are truly the glue behind a global public-president progress in new drugs and treatments for patients for 30 years.

We have tremendous takent her and who areved as C-Path's Chief Scientific Officer before being named CEO in 2034. He has been with the organization for 18 of its 20 years.

"Anytime anything important happens, whether it's day-to-day operations or something that develops for us and control for the president president of the structure of the structure of the structure of the structure for C-Path researchers and staff. They

Summer 2025 >>> BisTlucon 755

Summer 2025 >>> BisTlucon 675

Summer 2025 >>> BizTucson **75**